Search clinical trials for: Motesanib

Total 43 results

Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Amgen

Terminated

An Open Label Treatment Extension Study of AMG 706

Solid Tumors
Takeda

Terminated

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome

United States
Geron Corporation

Completed

Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (ET/PV)

Polycythemia Vera | Essential Thrombocythemia

United States, Germany, Switzerland
Geron Corporation

Available

Expanded Access for Treatment With Imetelstat

Myelodysplastic Syndromes
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Lymphoproliferative Disorder

United States
Geron Corporation

Completed

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis | Myeloid Malignancies

United States
National Cancer Institute (NCI)

Withdrawn

Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma

Lymphoma | Solid Tumors
Geron Corporation

Active, not recruiting

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
Amgen

Completed

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Thyroid Cancer
Amgen

Completed

Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Amgen

Completed

Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)

Gastrointestinal Cancer
GCP-Service International West GmbH
Saint-Louis Hospital, Paris, France; Groupe Francophone des Myelodysplasies; Australasian... and other collaborators

Recruiting

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Australia, France, Germany
Geron Corporation

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Myelofibrosis

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Amgen; Susan G. Komen Breast Cancer Foundation

Withdrawn

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer

United States
Amgen
Takeda

Completed

Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors

Advanced Gastrointestinal Stromal Tumor
NCIC Clinical Trials Group
Geron Corporation

Withdrawn

Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

Neuroblastoma

Canada
Geron Corporation

Completed

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Multiple Myeloma

United States
Geron Corporation

Completed

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Solid Tumor Malignancies

United States
Amgen

Completed

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Histologically or Cytologically Documented Solid Tumors
Amgen

Completed

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Tumors
Geron Corporation

Completed

Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

Lung Cancer

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Glioblastoma | Gliosarcoma | Ependymoma | Anaplastic Astrocytoma | Oligodendroglioma | Anaplastic Ependymoma | Giant Cell Glioblastoma | Astrocytoma, Grade II | Brainstem Tumors

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Small Intestine Cancer | Brain and Central Nervous System Tumors | Lymphoproliferative Disorder

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Withdrawn

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Rhabdomyosarcoma | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Hepatoblastoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Recurrent Childhood Liver Cancer
Geron Corporation

Recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Myelofibrosis

United States, Australia, Italy, India, United Kingdom, Israel, Taiwan, Poland, Malaysia, Argentina, Spain, Turkey, Belgium, Germany, Austria, Brazil, Bulgaria, Colombia, Denmark, France, Georgia, Hungary, Korea, Republic of, Portugal, ... and more
Amgen

Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Advanced Solid Tumors
Amgen

Terminated

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Locally Recurrent and Metastatic Breast Cancer
Geron Corporation

Completed

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Multiple Myeloma

United States
Amgen

Completed

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer
Amgen

Completed

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Locally Recurrent and Metastatic Breast Cancer
Swiss Group for Clinical Cancer Research

Completed

Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Switzerland
Amgen
Takeda

Terminated

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Non-Small Cell Lung Cancer
Amgen

Completed

Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

Solid Tumors
Geron Corporation

Completed

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Canada, Germany
Geron Corporation

Completed

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Myelofibrosis

United States, France, Italy, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Korea, Republic of, Canada
Amgen

Completed

Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer
Amgen

Terminated

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Advanced Non-squamous NSCLC
Amgen

Terminated

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Pancreatic Cancer | Esophageal Cancer | Lung Cancer
Geron Corporation

Completed

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Locally Recurrent or Metastatic Breast Cancer

United States, Canada
Geron Corporation

Completed

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Multiple Myeloma

United States
Children's Oncology Group

Not yet recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Juvenile Myelomonocytic Leukemia

Search clinical trials for: Motesanib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations